Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Osimertinib · 1 trial · 2 indications
The number of adverse events are graded by NCI CTCAE v5.0. The number of these dose-limiting toxicities (DLTs) experienced within the first treatment cycle (28 days) will be assessed to determine the RP2D.
| Arm | Type | Description |
|---|---|---|
| Osimertinib with Carotuximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Osimertinib | DRUG | Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance. |
| Carotuximab | DRUG | Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance. |
Inclusion Criteria: * Stage IV or recurrent/metastatic non-squamous NSCLC that harbors an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, etc). Local testing for EGFR mutations is acceptable provided it was performed in a CLIA certified lab. * Part I: Progre...
Top 20 of 84 competitors
Osimertinib is being studied for the treatment of Non Small Cell Lung Cancer (NSCLC), specifically in patients with EGFR-mutated advanced disease. It is an investigational small molecule being evaluated in a Phase 1 clinical trial in combination with carotuximab. The drug is not yet approved and remains in clinical development.
Osimertinib is a kinase inhibitor, as indicated by its '-tinib' suffix, which means it targets kinases involved in cancer cell growth. In the context of the ongoing trial, it is being studied in EGFR-mutated Non Small Cell Lung Cancer, suggesting it targets the EGFR kinase pathway. The drug is being evaluated in combination with carotuximab.
Osimertinib is being developed by Kairos Pharma, Ltd., a company listed under the ticker symbol KAPA. The company is conducting a Phase 1 clinical trial of the drug for Non Small Cell Lung Cancer. Kairos Pharma is the sponsor of the ongoing study.
Osimertinib is currently in Phase 1 clinical development. It is an investigational drug being studied for Non Small Cell Lung Cancer and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants in the United States.
Osimertinib is being evaluated in a Phase 1 clinical trial with the identifier NCT05401110, titled 'Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer.' The trial is recruiting 60 participants in the United States and is open to individuals aged 18 years and older.
Osimertinib is the generic name for the drug also known as Tagrisso. In the context of this development program, Kairos Pharma is studying osimertinib in combination with carotuximab for EGFR-mutated Non Small Cell Lung Cancer. The drug is being evaluated in a Phase 1 clinical trial.